Fortress Biotech Q1 2024 GAAP EPS $(1.03) Beats $(1.73) Estimate, Sales $13.030M Miss $14.131M Estimate
Fortress Biotech Q1 2024 GAAP EPS $(1.03) Beats $(1.73) Estimate, Sales $13.030M Miss $14.131M Estimate
Fortress Biotech 2024年第一季度GAAP每股收益美元（1.03美元）超過預期（1.73美元），銷售額爲130.3億美元，低於1413.1萬美元的預期
Fortress Biotech (NASDAQ:FBIO) reported quarterly losses of $(1.03) per share which beat the analyst consensus estimate of $(1.73) by 40.46 percent. The company reported quarterly sales of $13.030 million which missed the analyst consensus estimate of $14.131 million by 7.79 percent. This is a 4.84 percent increase over sales of $12.429 million the same period last year.
豐澤生物科技（納斯達克股票代碼：FBIO）公佈的季度虧損爲每股1.03美元，比分析師普遍預期的1.73美元（1.73美元）高出40.46個百分點。該公司公佈的季度銷售額爲1,303.0萬美元，比分析師普遍預期的1413.1萬美元低7.79％。這比去年同期的1242.9萬美元的銷售額增長了4.84％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。